The main manuscript presents analyses of the association of microalbuminuria and macroalbuminuria with the risk of a fall in eGFR below 60 ml/min/1.73m 2 on two or more successive occasions during 23 years of follow-up in the DCCT/EDIC. This Appendix presents parallel analyses of the risk of a single eGFR <60 mL/min/1.73m 2 whether or not it was confirmed or sustained on subsequent visits. Figure 1 shows that the proportion with normal AER up to the last visit among those with no abnormal GFR (51%) was greater than that (39%) at the time subjects first had a single eGFR <60 mL/min/1.73m 2 , as were the proportions with a history of microalbuminuria (42 versus 27%). Conversely, the proportion of subjects with a history of macroalbuminuria was greater among those with an eGFR <60 mL/min/1.73m 2 versus not (34% versus 7%). The percentages differed significantly between those with versus without an eGFR <60 mL/min/1.73m 2 (p<0.001). Appendix Table 1 compares the characteristics of the 202 subjects with an eGFR < 60 ml/min/1.73m 2 at any point in time versus the 1237 subjects who never had an eGFR < 60 ml/min/1.73m 2 . Compared with those with normal eGFR, participants who developed eGFR <60 mL/min/1.73m 2 were more likely to be female, older, in the DCCT conventional therapy group, and at DCCT baseline to have had clinical neuropathy, lower eGFR level, and higher LDL and triglyceride levels. They also had higher mean HbA1c levels during the DCCT and EDIC, and were more likely taking an ACE inhibitor during EDIC. Among those with an eGFR <60mL/min/1.73m 2 , the subset with a history of albuminuria, compared to those without, was more likely to be male, in the secondary cohort and the DCCT conventional treatment group, younger with longer diabetes duration, to have higher eGFR level, mean BP, AER, and triglyceride levels but lower HDL levels at DCCT baseline, to have higher mean HbA1c levels during the DCCT and EDIC, and to be taking ACE inhibitor during EDIC. The subset with microalbuminuria, compared to normal AER, had similar but less significant trends. Similar trends were also observed among the different AER categories for those with normal eGFR.
Appendix Figure 2 presents the cumulative incidence of a single eGFR <60mL/min/1.73m 2 in the cohort, reaching approximately 5% by 11 years and 22% by 23 years of follow-up.
Appendix Table 2 presents the Cox Proportional Hazard Model analyses, as in the main paper, of the risk of a single eGFR <60mL/min/1.73m 2 the within the categories of albuminuria using either the current level of AER or a history of microalbuminuria or macroalbuminuria at each visit. In the current albuminuria model, among those with normal AER at the current visit, 115 experienced an eGFR <60 mL/min/1.73m 2 corresponding to a crude rate of 4.2 subjects per 1000 patient years, about double that shown in Table 2 of the main paper for a sustained eGFR <60 mL/min/1.73m 2 . The rate was 8.6 per 1000 patient years among those with microalbuminuria at the current visit, and 67.9 among those with macroalbuminuria, both markedly greater than observed for sustained eGFR <60 mL/min/1.73m 2 . From a Cox proportional hazards model, adjusted for other factors, those with microalbuminuria had a 2.1 fold increased risk (hazard ratio) compared to those with normal AER (p <0.0001); and those with current macroalbuminuria had a 7.5 fold increased risk compared to those with normal AER (p <0.0001).
A history of macroalbuminuria (previously or currently) was likewise associated with an 4.2 fold increased risk of an eGFR <60 mL/min/1.73m 2 versus normal AER, but the risk among those with a history of microalbuminuria was not different from those with normal AER, as was observed in the analysis of a sustained eGFR <60 mL/min/1.73m 2 . Among those with albuminuria, although the absolute risks of a single eGFR <60 mL/min/1.73m 2 herein are greater than those of a sustained eGFR <60 mL/min/1.73m 2 presented in the main paper, the hazard ratios are smaller. This is because the risk of a single eGFR <60 mL/min/1.73m 2 among those with normal AER is also greater than that of a sustained eGFR <60 mL/min/1.73m
2 . This is a reflection of the within-patient biological variation in GFR over time, the sustained sustained eGFR <60 mL/min/1.73m 2 providing a more specific outcome criterion. Overall, therefore, the conclusions reached from the analyses of a single eGFR <60 mL/min/1.73m 2 are the same as those reached from analyses of a sustained eGFR <60 mL/min/1.73m 2 as presented in the main paper.
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